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Abstract
Ceramides	are	a	family	of	sphingophospholipids	synthesized	in	the	endoplasmic	reticulum,	which	mediate	cell
stress	responses,	including	apoptosis,	autophagy	and	senescence,	Serine	palmitoyltransferase	generates	3-
ketosphinganine,	which	is	reduced	to	dihydrosphingosine	(dihydrosphingosine).	N-Acylation	allows	the	formation
of	dihydroceramides,	which	are	subsequently	reduced	to	form	ceramides.	Once	synthesized,	ceramides	are
trafficked	from	the	ER	to	the	Golgi	bound	to	the	ceramide	transfer	protein,	CERT	(COL4A3BP,	Q9Y5P4).
Ceramide	can	be	metabolized	via	multiple	routes,	ensuring	tight	regulation	of	its	cellular	levels.	Addition	of
phosphocholine	generates	sphingomyelin	while	carbohydrate	is	added	to	form	glucosyl-	or	galactosylceramides.
Ceramidase	re-forms	sphingosine	or	sphinganine	from	ceramide	or	dihydroceramide.	Phosphorylation	of
ceramide	generates	ceramide	phosphate.	The	determination	of	accurate	kinetic	parameters	for	many	of	the
enzymes	in	the	sphingolipid	metabolic	pathway	is	complicated	by	the	lipophilic	nature	of	the	substrates.
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purely	as	an	adjunct	to	the	database	to	facilitate	the	recognition	of	citations	to	and	from	the	database	by	citation
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under	database	links.
GtoPdb	is	an	expert-driven	guide	to	pharmacological	targets	and	the	substances	that	act	on	them.	GtoPdb	is	a
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